Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
Piper-Vallillo AJ, Rotow JK, Aredo JV, Shaverdashvili K, Luo J, Carlisle JW, Husain H, Muzikansky A, Heist RS, Rangachari D, Ramalingam SS, Wakelee HA, Yu HA, Sequist LV, Bauml JM, Neal JW, Piotrowska Z. Piper-Vallillo AJ, et al. Among authors: carlisle jw. JTO Clin Res Rep. 2022 Apr 21;3(6):100328. doi: 10.1016/j.jtocrr.2022.100328. eCollection 2022 Jun. JTO Clin Res Rep. 2022. PMID: 35637759 Free PMC article.
A banner year for immunotherapy and targeted therapy.
Carlisle JW, Ramalingam SS. Carlisle JW, et al. Nat Rev Clin Oncol. 2019 Feb;16(2):79-80. doi: 10.1038/s41571-018-0138-4. Nat Rev Clin Oncol. 2019. PMID: 30538305 No abstract available.
Improving outcomes for brain metastases in EGFR mutated NSCLC.
Carlisle JW, Ramalingam SS. Carlisle JW, et al. Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S355-S359. doi: 10.21037/tlcr.2019.05.08. Transl Lung Cancer Res. 2019. PMID: 32038914 Free PMC article. No abstract available.
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
Sands JM, Mandrekar SJ, Kozono D, Oxnard GR, Hillman SL, Wigle DA, Govindan R, Carlisle J, Gray J, Salama JK, Raez L, Ganti A, Foster N, Malik S, Bradley J, Kelly K, Ramalingam SS, Stinchcombe TE. Sands JM, et al. Immunotherapy. 2021 Jun;13(9):727-734. doi: 10.2217/imt-2021-0019. Epub 2021 Apr 21. Immunotherapy. 2021. PMID: 33878954 Free PMC article.
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Osta BE, Carlisle J, Steuer C, Pakkala S, Leal T, Dhodapkar M, Liu Y, Chen Z, Owonikoko T, Ramalingam S. Osta BE, et al. Clin Lung Cancer. 2022 Nov;23(7):e400-e404. doi: 10.1016/j.cllc.2022.06.003. Epub 2022 Jun 22. Clin Lung Cancer. 2022. PMID: 35863963 Clinical Trial.
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era.
McCall NS, McGinnis HS, Janopaul-Naylor JR, Kesarwala AH, Tian S, Stokes WA, Shelton JW, Steuer CE, Carlisle JW, Leal T, Ramalingam SS, Bradley JD, Higgins KA. McCall NS, et al. Among authors: carlisle jw. Radiother Oncol. 2022 Sep;174:133-140. doi: 10.1016/j.radonc.2022.07.015. Epub 2022 Jul 20. Radiother Oncol. 2022. PMID: 35870727
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
Owonikoko TK, Dwivedi B, Chen Z, Zhang C, Barwick B, Ernani V, Zhang G, Gilbert-Ross M, Carlisle J, Khuri FR, Curran WJ, Ivanov AA, Fu H, Lonial S, Ramalingam SS, Sun SY, Waller EK, Sica GL. Owonikoko TK, et al. J Thorac Oncol. 2021 Mar;16(3):464-476. doi: 10.1016/j.jtho.2020.11.006. Epub 2020 Nov 25. J Thorac Oncol. 2021. PMID: 33248321 Free PMC article.
38 results